Squamous Non-Small Cell Lung Cancer
Conditions
Brief summary
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
Interventions
DRUGAtezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
DRUGCarboplatin
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
DRUGNab-Paclitaxel
Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
DRUGPaclitaxel
Paclitaxel 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\^2 IV.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC * Previously obtained archival tumor tissue or tissue obtained from biopsy at screening * Measurable disease as defined by RECIST v1.1 * Adequate hematologic and end organ function
Exclusion criteria
* Active or untreated central nervous system (CNS) metastasis * Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome * Pregnant or lactating women * History of autoimmune disease * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Positive test for Human Immunodeficiency Virus (HIV) * Active hepatitis B or hepatitis C * Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody * Severe infection within 4 weeks prior to randomization * Significant history of cardiovascular disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population | Up to approximately 30 months after first participant enrolled | PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population. |
| Overall Survival (OS) in the ITT Population | Up to approximately 39 months after first participant enrolled | OS is defined as the time between the date of randomization and date of death from any cause in the ITT population. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population | Up to approximately 30 months after first participant enrolled | PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population. |
| PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population | Up to approximately 30 months after first participant enrolled | PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population. |
| OS in the TC2/3 or IC2/3 Population | Up to approximately 39 months after first participant enrolled | OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population. |
| OS in the TC1/2/3 or IC1/2/3 Population | Up to approximately 39 months after first participant enrolled | OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population. |
| Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | Up to approximately 30 months after first participant enrolled | Proportion of participants with an objective response (CR or PR) in the ITT population. |
| Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | Up to approximately 30 months after first participant enrolled | Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population. |
| Event Free Rate at 1 and 2 Years in the ITT Population | 1 and 2 years | Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population. |
| Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population | Up to approximately 30 months after first participant enrolled | TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems. |
| TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population | Up to approximately 30 months after the first participant enrolled | TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi--item scale. In this instance, symptom deterioration will be determined as a \>= 10-point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a \>= 10-point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial\>=10-point increase above baseline followed by death within 3 weeks from the last assessment. A \>= 10-point change in the EORTC scale score is perceived by patients as clinically significant. |
| OS in the in the Teff Population | Up to approximately 39 months after first participant enrolled | OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population. |
| PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B) | Up to approximately 30 months after first participant enrolled | PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B. |
| OS in the ITT Population (Arm A and Arm B) | Up to approximately 39 months after first participant enrolled | OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B. |
| Percentage of Participants With Adverse Events | Up to approximately 68 months after first participant enrolled | Percentage of participants with at least one adverse event. |
| Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab | Up to approximately 30 months after first participant enrolled | Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab. |
| Maximum Observed Serum Atezolizumab Concentration (Cmax) | Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days) | Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes. |
| Minimum Observed Serum Atezolizumab Concentration (Cmin) | Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 30 months), at treatment discontinuation (up to 30 months), and at 120 days after the last dose of atezolizumab (up to approximately 30 months, each cycle is 21 days) | Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration. |
| Plasma Concentrations for Paclitaxel | Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) | Plasma concentrations for paclitaxel. |
| Plasma Concentrations for Nab-Paclitaxel | Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) | Plasma concentrations for nab-paclitaxel. |
| Plasma Concentrations for Carboplatin | Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days) | Plasma concentrations for carboplatin. |
| Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Baseline up to approximately 30 months after first participant enrolled | Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease) |
| PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population | Up to approximately 30 months after first participant enrolled | PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population. |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, France, Germany, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Peru, Portugal, Russia, Singapore, Slovakia, Spain, Taiwan, Ukraine, United States
Participant flow
Recruitment details
'Study Terminated By Sponsor' Reason for Not Completed is a data entry error; reason for not completed is unknown. The study was Completed and not Terminated.
Participants by arm
| Arm | Count |
|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin The induction phase of the study consisted of four or six cycles; carboplatin was administered on Day 1 of each 21-day cycle, nab-paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: nab-paclitaxel, then carboplatin. Participants who experienced disease progression at any time during the induction phase discontinued all study treatment. In the maintenance phase, participants received best supportive care. | 340 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin The induction phase of the study consisted of four or six cycles; atezolizumab and carboplatin were administered on Day 1 of each 21-day cycle. Nab-Paclitaxel was administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant. | 343 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin The induction phase of the study consisted of four or six cycles; atezolizumab, paclitaxel, and carboplatin were administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration was as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experienced no further clinical benefit at any time during the induction phase discontinued all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants began maintenance therapy with atezolizumab. Atezolizumab was continued as long as there was clinical benefit to the participant. | 338 |
| Total | 1,021 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 2 |
| Overall Study | Brain metastasis | 1 | 0 | 0 |
| Overall Study | Death | 252 | 245 | 243 |
| Overall Study | Discontinuation Matched Treatment Discontinuation | 0 | 0 | 1 |
| Overall Study | Hypercalcemia prior to C1D1 | 0 | 0 | 1 |
| Overall Study | Investigational Product Availability in Commercial Stock | 0 | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 2 | 2 |
| Overall Study | Moved into PTAP Study | 0 | 2 | 3 |
| Overall Study | Moved to Commercial Atezolizumab Use | 0 | 2 | 1 |
| Overall Study | Moved to Roll-Over Study | 0 | 15 | 13 |
| Overall Study | Participant Enrolled in Extended Protocol | 0 | 1 | 0 |
| Overall Study | Patient unable to receive carboplatin | 0 | 0 | 1 |
| Overall Study | Physician Decision | 0 | 5 | 3 |
| Overall Study | Protocol Violation | 1 | 0 | 1 |
| Overall Study | Randomized in error | 0 | 0 | 1 |
| Overall Study | Sponsor Request | 60 | 57 | 45 |
| Overall Study | Study Terminated By Sponsor | 0 | 1 | 1 |
| Overall Study | Withdrawal by Subject | 25 | 12 | 20 |
Baseline characteristics
| Characteristic | Arm C: Nab-Paclitaxel + Carboplatin | Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Arm A: Atezolizumab + Paclitaxel + Carboplatin | Total |
|---|---|---|---|---|
| Age, Continuous | 64.9 Years STANDARD_DEVIATION 8.1 | 64.0 Years STANDARD_DEVIATION 9.2 | 65.0 Years STANDARD_DEVIATION 8.3 | 64.6 Years STANDARD_DEVIATION 8.6 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 24 Participants | 27 Participants | 28 Participants | 79 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 299 Participants | 306 Participants | 297 Participants | 902 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 17 Participants | 10 Participants | 13 Participants | 40 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 3 Participants | 5 Participants |
| Race (NIH/OMB) Asian | 37 Participants | 41 Participants | 34 Participants | 112 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 4 Participants | 3 Participants | 14 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 6 Participants | 1 Participants | 8 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 2 Participants | 6 Participants | 12 Participants |
| Race (NIH/OMB) White | 290 Participants | 289 Participants | 290 Participants | 869 Participants |
| Sex: Female, Male Female | 63 Participants | 63 Participants | 60 Participants | 186 Participants |
| Sex: Female, Male Male | 277 Participants | 280 Participants | 278 Participants | 835 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 252 / 340 | 245 / 343 | 243 / 338 |
| other Total, other adverse events | 315 / 334 | 325 / 334 | 315 / 332 |
| serious Total, serious adverse events | 96 / 334 | 168 / 334 | 151 / 332 |
Outcome results
Primary
Overall Survival (OS) in the ITT Population
OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.
Time frame: Up to approximately 39 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Overall Survival (OS) in the ITT Population | 13.5 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Overall Survival (OS) in the ITT Population | 14.2 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Overall Survival (OS) in the ITT Population | 12.6 Months |
p-value: 0.158195% CI: [0.73, 1.05]Log Rank
Primary
Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.
Time frame: Up to approximately 30 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population | 5.6 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population | 6.5 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population | 5.6 Months |
p-value: 0.000695% CI: [0.64, 0.88]Log Rank
Secondary
Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population
Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease)
Time frame: Baseline up to approximately 30 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 1 | 0.18 Units on a scale | Standard Deviation 0.8 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 8 | -0.50 Units on a scale | Standard Deviation 2.12 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 61 | 0.00 Units on a scale | Standard Deviation 0.97 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Time of First Pd | -0.19 Units on a scale | Standard Deviation 1.13 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 82 | 0.43 Units on a scale | Standard Deviation 1.17 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 37 | -0.27 Units on a scale | Standard Deviation 1.37 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 64 | 0.63 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 60 | 0.14 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 38 | -0.19 Units on a scale | Standard Deviation 1.3 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 39 | -0.06 Units on a scale | Standard Deviation 1.53 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 7 | 1.33 Units on a scale | Standard Deviation 0.29 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 59 | 0.18 Units on a scale | Standard Deviation 0.81 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 40 | 0.06 Units on a scale | Standard Deviation 1.31 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Time of Last Tx Dose | -0.18 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 58 | 0.06 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 41 | 0.14 Units on a scale | Standard Deviation 1.21 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 58 | 0.80 Units on a scale | Standard Deviation 0.93 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 57 | 0.10 Units on a scale | Standard Deviation 0.81 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 42 | -0.10 Units on a scale | Standard Deviation 1.5 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 6 | -0.17 Units on a scale | Standard Deviation 1.17 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 56 | 0.14 Units on a scale | Standard Deviation 1.05 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 43 | 0.13 Units on a scale | Standard Deviation 1.59 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 1 | 0.03 Units on a scale | Standard Deviation 1.3 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 55 | 0.29 Units on a scale | Standard Deviation 1.05 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 47 | 0.18 Units on a scale | Standard Deviation 1.29 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 2 | -0.10 Units on a scale | Standard Deviation 1.23 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 54 | 0.08 Units on a scale | Standard Deviation 0.89 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 3 | -0.09 Units on a scale | Standard Deviation 1.13 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 11 | -0.31 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 4 | -0.13 Units on a scale | Standard Deviation 1.15 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 53 | 0.21 Units on a scale | Standard Deviation 0.78 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 48 | -0.08 Units on a scale | Standard Deviation 1.53 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 5 | -0.02 Units on a scale | Standard Deviation 1.34 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 6 | -0.22 Units on a scale | Standard Deviation 0.99 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 112 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 111 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 14 | -0.31 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 7 | 0.33 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 49 | -0.23 Units on a scale | Standard Deviation 1.59 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 17 | -0.18 Units on a scale | Standard Deviation 1.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Survival Follow-Up Month 8 | -0.75 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 110 | 0.00 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 52 | 0.15 Units on a scale | Standard Deviation 1.3 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 18 | -0.26 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 1 | 0.01 Units on a scale | Standard Deviation 0.78 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 108 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 43 | 0.48 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 107 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 53 | 0.18 Units on a scale | Standard Deviation 1.27 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 55 | 0.21 Units on a scale | Standard Deviation 1.37 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 103 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 21 | -0.36 Units on a scale | Standard Deviation 1.01 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 3 | -0.14 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 102 | 1.00 Units on a scale | Standard Deviation 1.32 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 75 | 0.70 Units on a scale | Standard Deviation 0.99 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 101 | 1.17 Units on a scale | Standard Deviation 1.61 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 25 | -0.28 Units on a scale | Standard Deviation 1.18 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 61 | 0.61 Units on a scale | Standard Deviation 1.29 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 5 | -0.04 Units on a scale | Standard Deviation 1.14 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 4 | -0.19 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 96 | 1.17 Units on a scale | Standard Deviation 1.61 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 95 | 0.67 Units on a scale | Standard Deviation 2.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 26 | -0.41 Units on a scale | Standard Deviation 1.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 62 | 0.05 Units on a scale | Standard Deviation 1.34 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 77 | 0.73 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 94 | 0.67 Units on a scale | Standard Deviation 2.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 66 | 0.42 Units on a scale | Standard Deviation 1.53 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 5 | -0.17 Units on a scale | Standard Deviation 1.1 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 57 | 0.74 Units on a scale | Standard Deviation 0.8 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 45 | 0.10 Units on a scale | Standard Deviation 1.24 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 27 | -0.27 Units on a scale | Standard Deviation 1.11 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 70 | 0.30 Units on a scale | Standard Deviation 1.79 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 2 | -0.02 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 44 | -0.05 Units on a scale | Standard Deviation 1.24 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 71 | 0.08 Units on a scale | Standard Deviation 1.72 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 4 | -0.09 Units on a scale | Standard Deviation 1.32 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 90 | 0.67 Units on a scale | Standard Deviation 2.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 72 | 0.25 Units on a scale | Standard Deviation 1.7 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 6 | -0.35 Units on a scale | Standard Deviation 1.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 87 | 1.00 Units on a scale | Standard Deviation 1.73 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 73 | 0.42 Units on a scale | Standard Deviation 1.53 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 3 | -0.18 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 89 | 0.83 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 38 | 0.02 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 79 | 0.08 Units on a scale | Standard Deviation 1.72 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 2 | 0.03 Units on a scale | Standard Deviation 1.04 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 3 | -0.09 Units on a scale | Standard Deviation 0.9 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 37 | -0.08 Units on a scale | Standard Deviation 1.11 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 80 | 0.14 Units on a scale | Standard Deviation 1.65 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 56 | 0.69 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 36 | -0.05 Units on a scale | Standard Deviation 0.93 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 28 | -0.34 Units on a scale | Standard Deviation 1.1 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Survival Follow-Up Month 1 | -0.03 Units on a scale | Standard Deviation 1.13 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 34 | -0.03 Units on a scale | Standard Deviation 0.93 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 84 | 0.00 Units on a scale | Standard Deviation 1.84 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 82 | 0.07 Units on a scale | Standard Deviation 1.62 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 4 | -0.26 Units on a scale | Standard Deviation 0.92 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 7 | -0.38 Units on a scale | Standard Deviation 1.12 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 33 | -0.31 Units on a scale | Standard Deviation 1.11 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 32 | -0.17 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 31 | -0.46 Units on a scale | Standard Deviation 1.14 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 55 | 0.82 Units on a scale | Standard Deviation 0.93 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 83 | 0.00 Units on a scale | Standard Deviation 1.77 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Time of Last Tx Dose | -0.31 Units on a scale | Standard Deviation 1.1 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 8 | -0.35 Units on a scale | Standard Deviation 1.12 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 1 | 0.04 Units on a scale | Standard Deviation 0.93 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Time of First Pd | -0.15 Units on a scale | Standard Deviation 1.05 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 63 | 0.58 Units on a scale | Standard Deviation 1.14 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Time of First Pd | 0.38 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 9 | -0.36 Units on a scale | Standard Deviation 1 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 54 | 0.71 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 118 | 1.00 Units on a scale | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 10 | -0.20 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 5 | -0.18 Units on a scale | Standard Deviation 1.02 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 2 | -0.08 Units on a scale | Standard Deviation 0.89 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 65 | 0.80 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 117 | 0.40 Units on a scale | Standard Deviation 0.28 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 116 | 0.40 Units on a scale | Standard Deviation 0.57 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 11 | -0.27 Units on a scale | Standard Deviation 1.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 53 | 0.70 Units on a scale | Standard Deviation 0.85 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 115 | 0.50 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 12 | -0.34 Units on a scale | Standard Deviation 1.05 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 114 | -0.25 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 114 | 0.50 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 13 | -0.31 Units on a scale | Standard Deviation 1.24 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 5 | 0.21 Units on a scale | Standard Deviation 0.89 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 113 | 1.00 Units on a scale | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 14 | -0.32 Units on a scale | Standard Deviation 1.18 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 52 | 0.60 Units on a scale | Standard Deviation 0.81 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 112 | 0.50 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 15 | -0.45 Units on a scale | Standard Deviation 1.19 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 115 | -0.25 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 111 | 0.30 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 16 | -0.28 Units on a scale | Standard Deviation 1.1 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 7 | 0.20 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 116 | 0.75 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 17 | -0.32 Units on a scale | Standard Deviation 1.11 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 51 | 0.71 Units on a scale | Standard Deviation 0.92 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 115 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 18 | -0.28 Units on a scale | Standard Deviation 1.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 116 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 114 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 19 | -0.18 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 16 | 0.45 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 109 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 20 | -0.23 Units on a scale | Standard Deviation 1.07 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 50 | 0.41 Units on a scale | Standard Deviation 0.84 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 108 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 21 | -0.37 Units on a scale | Standard Deviation 1.02 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 117 | -0.25 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 107 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 66 | 0.70 Units on a scale | Standard Deviation 1.02 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 106 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 23 | -0.29 Units on a scale | Standard Deviation 1.16 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 49 | 0.46 Units on a scale | Standard Deviation 0.99 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 99 | 0.83 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 24 | -0.43 Units on a scale | Standard Deviation 1.15 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 118 | 0.00 Units on a scale | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 98 | 0.50 Units on a scale | Standard Deviation 0.5 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 25 | -0.25 Units on a scale | Standard Deviation 1.24 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 62 | 0.58 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 97 | 1.00 Units on a scale | Standard Deviation 0.5 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 26 | -0.50 Units on a scale | Standard Deviation 1.2 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 48 | 0.32 Units on a scale | Standard Deviation 0.88 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 96 | 0.83 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 27 | -0.35 Units on a scale | Standard Deviation 1.29 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 22 | -0.27 Units on a scale | Standard Deviation 1.18 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 91 | 0.67 Units on a scale | Standard Deviation 0.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 28 | -0.22 Units on a scale | Standard Deviation 1.27 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 47 | 0.32 Units on a scale | Standard Deviation 0.85 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 90 | 1.00 Units on a scale | Standard Deviation 0.5 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 29 | -0.30 Units on a scale | Standard Deviation 1.23 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 61 | 0.91 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 88 | 0.67 Units on a scale | Standard Deviation 0.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 30 | -0.15 Units on a scale | Standard Deviation 1.36 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 46 | 0.36 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 84 | 0.20 Units on a scale | Standard Deviation 1.3 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 31 | -0.49 Units on a scale | Standard Deviation 1.25 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 60 | 0.67 Units on a scale | Standard Deviation 0.86 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 78 | 0.00 Units on a scale | Standard Deviation 1.26 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 32 | -0.29 Units on a scale | Standard Deviation 1.16 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 8 | 0.26 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 77 | 0.25 Units on a scale | Standard Deviation 1.29 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 33 | -0.29 Units on a scale | Standard Deviation 1.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 6 | -0.27 Units on a scale | Standard Deviation 1.05 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 22 | 0.50 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 76 | 0.00 Units on a scale | Standard Deviation 1.38 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 6 | 0.17 Units on a scale | Standard Deviation 0.97 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 75 | 0.08 Units on a scale | Standard Deviation 1.24 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 7 | -0.27 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 34 | -0.15 Units on a scale | Standard Deviation 1.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 59 | 0.78 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 4 | 0.17 Units on a scale | Standard Deviation 0.89 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 69 | 0.20 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 68 | 0.00 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 23 | 0.44 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 8 | -0.26 Units on a scale | Standard Deviation 1.11 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 35 | -0.26 Units on a scale | Standard Deviation 1.31 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 3 | 0.06 Units on a scale | Standard Deviation 0.83 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 2 | 0.13 Units on a scale | Standard Deviation 0.75 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 67 | -0.30 Units on a scale | Standard Deviation 0.67 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 66 | 0.08 Units on a scale | Standard Deviation 0.86 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 65 | 0.08 Units on a scale | Standard Deviation 0.97 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 9 | -0.32 Units on a scale | Standard Deviation 1.16 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 81 | 0.08 Units on a scale | Standard Deviation 1.02 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 106 | 0.30 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 28 | 0.24 Units on a scale | Standard Deviation 0.83 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 50 | 0.23 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 89 | 0.53 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 27 | 0.31 Units on a scale | Standard Deviation 0.8 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 51 | 0.05 Units on a scale | Standard Deviation 0.88 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 59 | 0.00 Units on a scale | Standard Deviation 1.32 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 26 | 0.20 Units on a scale | Standard Deviation 0.84 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 52 | 0.12 Units on a scale | Standard Deviation 0.79 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 62 | -0.05 Units on a scale | Standard Deviation 0.86 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 102 | 0.40 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 25 | 0.27 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 88 | 0.40 Units on a scale | Standard Deviation 0.69 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 24 | 0.25 Units on a scale | Standard Deviation 1.01 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 83 | 0.30 Units on a scale | Standard Deviation 1.44 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 63 | 0.19 Units on a scale | Standard Deviation 0.7 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 60 | 0.09 Units on a scale | Standard Deviation 1.59 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 18 | 0.46 Units on a scale | Standard Deviation 0.93 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 64 | 0.13 Units on a scale | Standard Deviation 1.16 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 51 | 0.55 Units on a scale | Standard Deviation 1.39 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 70 | 0.20 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 87 | 0.40 Units on a scale | Standard Deviation 0.4 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 17 | 0.55 Units on a scale | Standard Deviation 0.99 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 71 | -0.17 Units on a scale | Standard Deviation 1.21 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 86 | 1.33 Units on a scale | Standard Deviation 1.45 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 15 | 0.36 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 72 | 0.00 Units on a scale | Standard Deviation 1.38 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 63 | -0.44 Units on a scale | Standard Deviation 1.21 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 14 | 0.42 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 73 | 0.00 Units on a scale | Standard Deviation 1.38 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 45 | 0.15 Units on a scale | Standard Deviation 1.7 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 13 | 0.40 Units on a scale | Standard Deviation 1.03 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 74 | 0.07 Units on a scale | Standard Deviation 0.89 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 85 | 0.70 Units on a scale | Standard Deviation 0.5 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 12 | 0.44 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 64 | 0.19 Units on a scale | Standard Deviation 1.49 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 11 | 0.40 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 79 | 0.00 Units on a scale | Standard Deviation 1.38 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 101 | 0.40 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 10 | 0.37 Units on a scale | Standard Deviation 0.99 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 80 | 0.21 Units on a scale | Standard Deviation 1.07 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 9 | 0.23 Units on a scale | Standard Deviation 0.97 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 85 | 1.00 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 84 | 0.16 Units on a scale | Standard Deviation 0.59 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 8 | 0.10 Units on a scale | Standard Deviation 0.14 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 86 | 1.17 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 65 | 0.25 Units on a scale | Standard Deviation 1.37 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 7 | 1.07 Units on a scale | Standard Deviation 1.36 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 87 | 0.83 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 15 | -0.39 Units on a scale | Standard Deviation 1.11 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 6 | 0.63 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 92 | 1.00 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 83 | 0.28 Units on a scale | Standard Deviation 0.69 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 5 | 0.66 Units on a scale | Standard Deviation 1.02 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 93 | 1.00 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 67 | -0.50 Units on a scale | Standard Deviation 1.27 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 4 | 0.57 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 94 | 0.83 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 108 | 0.60 Units on a scale | Standard Deviation 0.28 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 3 | 0.67 Units on a scale | Standard Deviation 1.06 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 95 | 0.83 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 100 | 1.00 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 82 | 0.57 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 2 | 0.71 Units on a scale | Standard Deviation 0.89 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 101 | 0.83 Units on a scale | Standard Deviation 0.58 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 68 | 0.08 Units on a scale | Standard Deviation 1.77 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Survival Follow-Up Month 1 | 0.56 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 102 | 0.67 Units on a scale | Standard Deviation 0.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 100 | 0.50 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Time of Last Tx Dose | 0.43 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 103 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 81 | 0.50 Units on a scale | Standard Deviation 0.92 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 110 | 0.60 Units on a scale | Standard Deviation 0.28 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 104 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 69 | 0.70 Units on a scale | Standard Deviation 1.6 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 109 | 0.80 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 105 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 110 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 16 | -0.19 Units on a scale | Standard Deviation 1.19 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 111 | 0.75 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 80 | 0.60 Units on a scale | Standard Deviation 0.78 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 118 | 0.50 Units on a scale | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 112 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 79 | 0.57 Units on a scale | Standard Deviation 0.77 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 117 | 0.75 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 113 | 0.50 Units on a scale | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 74 | 0.43 Units on a scale | Standard Deviation 1.62 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 105 | 0.40 Units on a scale | Standard Deviation 0.57 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 78 | 0.57 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 75 | 0.25 Units on a scale | Standard Deviation 1.7 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 99 | 0.47 Units on a scale | Standard Deviation 0.46 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 76 | 0.67 Units on a scale | Standard Deviation 0.9 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 76 | 0.00 Units on a scale | Standard Deviation 1.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 98 | 0.73 Units on a scale | Standard Deviation 0.5 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 74 | 0.74 Units on a scale | Standard Deviation 0.96 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 77 | 0.00 Units on a scale | Standard Deviation 1.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 46 | 0.00 Units on a scale | Standard Deviation 1.39 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 73 | 0.67 Units on a scale | Standard Deviation 1.07 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 78 | 0.07 Units on a scale | Standard Deviation 1.62 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 29 | -0.38 Units on a scale | Standard Deviation 1.15 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 19 | -0.29 Units on a scale | Standard Deviation 1.05 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 81 | 0.25 Units on a scale | Standard Deviation 1.7 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 97 | 0.67 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 72 | 0.57 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 71 | 0.70 Units on a scale | Standard Deviation 0.91 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 30 | -0.29 Units on a scale | Standard Deviation 1.15 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 85 | 1.13 Units on a scale | Standard Deviation 1.31 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 54 | 0.08 Units on a scale | Standard Deviation 1.17 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 70 | 1.00 Units on a scale | Standard Deviation 0.6 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 107 | 0.60 Units on a scale | Standard Deviation 0.28 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 86 | 1.33 Units on a scale | Standard Deviation 1.53 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 69 | 0.96 Units on a scale | Standard Deviation 0.59 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 96 | 0.33 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 35 | -0.14 Units on a scale | Standard Deviation 1.01 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 68 | 0.63 Units on a scale | Standard Deviation 0.98 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 67 | 0.52 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 39 | 0.00 Units on a scale | Standard Deviation 1.05 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 12 | -0.30 Units on a scale | Standard Deviation 1.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 88 | 0.83 Units on a scale | Standard Deviation 1.44 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 95 | 0.53 Units on a scale | Standard Deviation 0.23 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 45 | 0.32 Units on a scale | Standard Deviation 1.04 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 89 | 0.67 Units on a scale | Standard Deviation 2.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 20 | -0.29 Units on a scale | Standard Deviation 1.09 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 44 | 0.22 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 40 | 0.10 Units on a scale | Standard Deviation 1.12 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 44 | -0.08 Units on a scale | Standard Deviation 1.52 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 10 | -0.28 Units on a scale | Standard Deviation 1.02 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 41 | 0.07 Units on a scale | Standard Deviation 1.21 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 94 | 0.67 Units on a scale | Standard Deviation 0.7 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 42 | 0.37 Units on a scale | Standard Deviation 0.82 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 42 | -0.04 Units on a scale | Standard Deviation 1.16 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 22 | -0.25 Units on a scale | Standard Deviation 1.13 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 41 | 0.45 Units on a scale | Standard Deviation 0.92 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 43 | -0.02 Units on a scale | Standard Deviation 0.87 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 46 | 0.03 Units on a scale | Standard Deviation 0.95 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 91 | 1.17 Units on a scale | Standard Deviation 1.61 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 104 | 0.50 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 40 | 0.38 Units on a scale | Standard Deviation 0.74 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 56 | 0.05 Units on a scale | Standard Deviation 1.39 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 92 | 0.88 Units on a scale | Standard Deviation 1.44 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 13 | -0.23 Units on a scale | Standard Deviation 1.14 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 39 | 0.39 Units on a scale | Standard Deviation 0.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 38 | 0.31 Units on a scale | Standard Deviation 0.75 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 93 | 1.50 Units on a scale | Standard Deviation 2.12 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 93 | 0.40 Units on a scale | Standard Deviation 0.28 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 21 | 0.51 Units on a scale | Standard Deviation 0.94 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 97 | 1.17 Units on a scale | Standard Deviation 1.61 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 57 | 0.05 Units on a scale | Standard Deviation 1.46 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 20 | 0.37 Units on a scale | Standard Deviation 0.97 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 98 | 0.83 Units on a scale | Standard Deviation 2.02 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 36 | -0.24 Units on a scale | Standard Deviation 1.34 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 19 | 0.48 Units on a scale | Standard Deviation 0.97 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 99 | 0.67 Units on a scale | Standard Deviation 2.08 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 92 | 0.75 Units on a scale | Standard Deviation 0.66 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 37 | 0.24 Units on a scale | Standard Deviation 0.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 100 | 1.25 Units on a scale | Standard Deviation 1.77 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 104 | 0.25 Units on a scale | Standard Deviation 0.35 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 58 | 0.13 Units on a scale | Standard Deviation 1.25 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 36 | 0.32 Units on a scale | Standard Deviation 0.68 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 105 | 0.50 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 103 | 0.70 Units on a scale | Standard Deviation 0.42 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 35 | 0.35 Units on a scale | Standard Deviation 0.88 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 106 | 0.00 Units on a scale | Standard Deviation 0 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 91 | 0.33 Units on a scale | Standard Deviation 0.31 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 23 | -0.26 Units on a scale | Standard Deviation 1.19 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 34 | 0.32 Units on a scale | Standard Deviation 0.69 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 109 | -0.50 Units on a scale | Standard Deviation 0.71 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 50 | 0.00 Units on a scale | Standard Deviation 1.73 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 33 | 0.39 Units on a scale | Standard Deviation 0.74 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 32 | 0.28 Units on a scale | Standard Deviation 0.79 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 113 | 0.00 Units on a scale | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 31 | 0.34 Units on a scale | Standard Deviation 0.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 47 | 0.10 Units on a scale | Standard Deviation 1.15 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 90 | 0.27 Units on a scale | Standard Deviation 0.31 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 30 | 0.30 Units on a scale | Standard Deviation 0.82 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 48 | 0.00 Units on a scale | Standard Deviation 1.22 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 24 | -0.28 Units on a scale | Standard Deviation 1.14 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 29 | 0.30 Units on a scale | Standard Deviation 0.82 |
| Arm C: Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 49 | -0.12 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 43 | 0.16 Units on a scale | Standard Deviation 0.76 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 38 | -0.09 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 44 | -0.25 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 45 | -0.21 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 46 | -0.16 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 12 | -0.25 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 49 | -0.24 Units on a scale | Standard Deviation 1.05 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 50 | -0.17 Units on a scale | Standard Deviation 0.98 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 51 | -0.16 Units on a scale | Standard Deviation 1.07 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 15 | -0.23 Units on a scale | Standard Deviation 1.03 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 16 | -0.18 Units on a scale | Standard Deviation 1.14 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 53 | -0.12 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 54 | -0.18 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 19 | -0.29 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 20 | -0.24 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 22 | -0.27 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 56 | -0.22 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 57 | -0.22 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 58 | -0.22 Units on a scale | Standard Deviation 0.86 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 23 | -0.30 Units on a scale | Standard Deviation 1.07 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 24 | -0.33 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 59 | -0.20 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 60 | -0.27 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 63 | -0.12 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 64 | -0.13 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 65 | -0.13 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 67 | -0.08 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 68 | -0.09 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 69 | -0.15 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 74 | -0.10 Units on a scale | Standard Deviation 1.14 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 75 | -0.17 Units on a scale | Standard Deviation 0.89 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 76 | -0.02 Units on a scale | Standard Deviation 1.03 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 77 | 0.00 Units on a scale | Standard Deviation 1.15 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 29 | -0.33 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 81 | -0.25 Units on a scale | Standard Deviation 0.9 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 85 | -0.35 Units on a scale | Standard Deviation 1.03 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 34 | -0.34 Units on a scale | Standard Deviation 0.84 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 86 | -0.37 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 39 | -0.46 Units on a scale | Standard Deviation 1.05 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 88 | -0.20 Units on a scale | Standard Deviation 1.22 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 89 | -0.14 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 40 | -0.39 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 41 | -0.43 Units on a scale | Standard Deviation 1.1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 42 | -0.41 Units on a scale | Standard Deviation 1.05 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 91 | -0.42 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 46 | -0.38 Units on a scale | Standard Deviation 1.11 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 92 | -0.15 Units on a scale | Standard Deviation 1.2 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 93 | 0.00 Units on a scale | Standard Deviation 1.24 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 97 | -0.18 Units on a scale | Standard Deviation 1.54 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 98 | 0.05 Units on a scale | Standard Deviation 1.48 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 99 | 0.00 Units on a scale | Standard Deviation 1.53 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 104 | -0.56 Units on a scale | Standard Deviation 1.05 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 105 | -0.50 Units on a scale | Standard Deviation 0.84 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 106 | -0.72 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 108 | -0.30 Units on a scale | Standard Deviation 1.25 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 109 | -0.90 Units on a scale | Standard Deviation 1.24 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 47 | -0.38 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 48 | -0.41 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 49 | -0.44 Units on a scale | Standard Deviation 1.1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 50 | -0.29 Units on a scale | Standard Deviation 1.16 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 51 | -0.22 Units on a scale | Standard Deviation 1.2 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 62 | -0.29 Units on a scale | Standard Deviation 1.29 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 82 | -0.33 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 63 | -0.30 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 64 | -0.27 Units on a scale | Standard Deviation 1.21 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 70 | -0.28 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 71 | -0.15 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 72 | -0.19 Units on a scale | Standard Deviation 1.1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 73 | -0.22 Units on a scale | Standard Deviation 1.15 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 74 | -0.22 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 84 | -0.10 Units on a scale | Standard Deviation 1.28 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 79 | -0.04 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 85 | -0.24 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 86 | -0.27 Units on a scale | Standard Deviation 1.28 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 91 | -0.58 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 92 | -0.19 Units on a scale | Standard Deviation 1.18 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 93 | -0.42 Units on a scale | Standard Deviation 1.26 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 94 | -0.41 Units on a scale | Standard Deviation 1.26 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 100 | -0.35 Units on a scale | Standard Deviation 1.16 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 101 | -0.20 Units on a scale | Standard Deviation 1.32 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 102 | 0.00 Units on a scale | Standard Deviation 1.3 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 103 | -0.56 Units on a scale | Standard Deviation 1.07 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 104 | -0.38 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 110 | 0.50 Units on a scale | Standard Deviation 1.8 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 111 | -0.13 Units on a scale | Standard Deviation 1.93 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 112 | 0.17 Units on a scale | Standard Deviation 1.44 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 113 | 0.13 Units on a scale | Standard Deviation 1.75 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 117 | -0.25 Units on a scale | Standard Deviation 1.77 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 118 | 1.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 109 | -0.40 Units on a scale | Standard Deviation 0.47 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Time of Last Tx Dose | 0.28 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 9 | 0.26 Units on a scale | Standard Deviation 0.85 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 10 | 0.34 Units on a scale | Standard Deviation 0.94 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 11 | 0.31 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 12 | 0.41 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 13 | 0.32 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 14 | 0.29 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 15 | 0.32 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 16 | 0.32 Units on a scale | Standard Deviation 0.93 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 24 | 0.20 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 25 | 0.18 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 26 | 0.31 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 28 | 0.17 Units on a scale | Standard Deviation 0.86 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 29 | 0.19 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 30 | 0.12 Units on a scale | Standard Deviation 0.94 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 31 | 0.18 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 32 | 0.09 Units on a scale | Standard Deviation 0.84 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 33 | 0.02 Units on a scale | Standard Deviation 0.85 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 34 | 0.05 Units on a scale | Standard Deviation 0.76 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 35 | 0.04 Units on a scale | Standard Deviation 0.82 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 36 | 0.11 Units on a scale | Standard Deviation 0.82 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 19 | 0.28 Units on a scale | Standard Deviation 0.98 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 20 | 0.28 Units on a scale | Standard Deviation 0.93 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 21 | 0.23 Units on a scale | Standard Deviation 0.98 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 37 | 0.16 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 38 | 0.10 Units on a scale | Standard Deviation 0.78 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 39 | 0.04 Units on a scale | Standard Deviation 0.87 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 40 | 0.24 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 41 | 0.13 Units on a scale | Standard Deviation 0.84 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 42 | 0.05 Units on a scale | Standard Deviation 0.81 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 44 | 0.11 Units on a scale | Standard Deviation 0.88 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 45 | 0.20 Units on a scale | Standard Deviation 0.84 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 67 | 0.04 Units on a scale | Standard Deviation 1.15 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 68 | 0.01 Units on a scale | Standard Deviation 1.07 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 23 | 0.30 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 69 | 0.06 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 70 | 0.16 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 71 | 0.22 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 72 | 0.25 Units on a scale | Standard Deviation 1.16 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 73 | 0.10 Units on a scale | Standard Deviation 1.18 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 74 | 0.10 Units on a scale | Standard Deviation 1.15 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 75 | 0.05 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 76 | 0.25 Units on a scale | Standard Deviation 1.33 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 77 | 0.04 Units on a scale | Standard Deviation 1.36 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 78 | 0.09 Units on a scale | Standard Deviation 1.24 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 79 | 0.16 Units on a scale | Standard Deviation 1.29 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 80 | -0.13 Units on a scale | Standard Deviation 1.17 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 81 | -0.02 Units on a scale | Standard Deviation 1.17 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 82 | -0.05 Units on a scale | Standard Deviation 1.16 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 83 | -0.08 Units on a scale | Standard Deviation 1.26 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 84 | -0.17 Units on a scale | Standard Deviation 1.23 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 86 | -0.23 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 87 | 0.08 Units on a scale | Standard Deviation 1.45 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 88 | -0.21 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 89 | -0.13 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 90 | -0.32 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 91 | -0.52 Units on a scale | Standard Deviation 0.81 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 92 | -0.28 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 93 | -0.23 Units on a scale | Standard Deviation 0.93 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 94 | -0.38 Units on a scale | Standard Deviation 0.85 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 95 | -0.07 Units on a scale | Standard Deviation 1.21 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 96 | -0.02 Units on a scale | Standard Deviation 1.21 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 97 | -0.22 Units on a scale | Standard Deviation 1.18 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 98 | -0.18 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 99 | -0.26 Units on a scale | Standard Deviation 1.25 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 100 | -0.24 Units on a scale | Standard Deviation 1.24 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 101 | -0.26 Units on a scale | Standard Deviation 1.23 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 102 | -0.67 Units on a scale | Standard Deviation 0.89 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 103 | -0.60 Units on a scale | Standard Deviation 0.73 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 104 | -0.63 Units on a scale | Standard Deviation 0.82 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 105 | -0.20 Units on a scale | Standard Deviation 0.33 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 106 | -0.24 Units on a scale | Standard Deviation 0.31 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 107 | -0.17 Units on a scale | Standard Deviation 0.35 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 108 | -0.36 Units on a scale | Standard Deviation 0.43 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 22 | 0.25 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 113 | -0.50 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 2 | 0.00 Units on a scale | Standard Deviation 0.9 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 35 | -0.38 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 38 | -0.36 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 115 | -0.88 Units on a scale | Standard Deviation 1.31 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 17 | 0.25 Units on a scale | Standard Deviation 0.9 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 18 | 0.28 Units on a scale | Standard Deviation 0.93 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 27 | 0.21 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 85 | -0.16 Units on a scale | Standard Deviation 1.11 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 1 | 0.14 Units on a scale | Standard Deviation 0.87 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 2 | 0.09 Units on a scale | Standard Deviation 0.98 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 114 | -0.50 Units on a scale | Standard Deviation 1.32 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 115 | -0.50 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 116 | -0.67 Units on a scale | Standard Deviation 1.15 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 117 | -1.00 Units on a scale | Standard Deviation 1.41 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 118 | 0.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 119 | 0.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 120 | 0.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 121 | 0.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 122 | 0.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 123 | 0.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 124 | 0.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Time of First Pd | 0.10 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Time of Last Tx Dose | 0.01 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 1 | 0.03 Units on a scale | Standard Deviation 0.82 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 3 | -0.03 Units on a scale | Standard Deviation 0.78 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 4 | -0.05 Units on a scale | Standard Deviation 0.98 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 5 | -0.08 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 6 | -0.13 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 3 | -0.10 Units on a scale | Standard Deviation 1.03 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 7 | -0.18 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 8 | -0.17 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 4 | -0.16 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 9 | -0.19 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 5 | -0.24 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 10 | -0.16 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 11 | -0.24 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 12 | -0.21 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 13 | -0.22 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 14 | -0.24 Units on a scale | Standard Deviation 0.88 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 15 | -0.28 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 16 | -0.14 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 17 | -0.17 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 18 | -0.13 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 19 | -0.10 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 20 | -0.15 Units on a scale | Standard Deviation 0.94 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 21 | -0.07 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 22 | -0.08 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 23 | 0.04 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 24 | -0.15 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 25 | -0.17 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 26 | -0.06 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 27 | -0.17 Units on a scale | Standard Deviation 1.03 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 28 | -0.12 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 29 | -0.11 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 30 | -0.21 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 31 | -0.16 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 32 | -0.15 Units on a scale | Standard Deviation 0.88 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 6 | -0.22 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 33 | -0.20 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 7 | -0.27 Units on a scale | Standard Deviation 1.07 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 34 | -0.04 Units on a scale | Standard Deviation 0.89 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 80 | -0.45 Units on a scale | Standard Deviation 1.17 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 8 | -0.26 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 35 | -0.14 Units on a scale | Standard Deviation 0.88 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 81 | -0.31 Units on a scale | Standard Deviation 1.14 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 9 | -0.27 Units on a scale | Standard Deviation 1.01 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 36 | -0.06 Units on a scale | Standard Deviation 0.88 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 37 | 0.05 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 39 | -0.18 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 40 | -0.11 Units on a scale | Standard Deviation 0.85 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 41 | -0.14 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 42 | -0.05 Units on a scale | Standard Deviation 0.94 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 43 | -0.08 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 10 | -0.28 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 47 | -0.16 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 11 | -0.27 Units on a scale | Standard Deviation 1.14 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 48 | -0.17 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 13 | -0.28 Units on a scale | Standard Deviation 1.17 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 14 | -0.29 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 17 | -0.21 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 52 | -0.09 Units on a scale | Standard Deviation 0.98 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 18 | -0.34 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 55 | -0.11 Units on a scale | Standard Deviation 0.79 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 21 | -0.26 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 25 | -0.31 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 61 | -0.23 Units on a scale | Standard Deviation 0.83 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 62 | -0.03 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 66 | 0.00 Units on a scale | Standard Deviation 1.26 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 26 | -0.32 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 70 | -0.06 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 71 | -0.13 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 72 | -0.20 Units on a scale | Standard Deviation 0.94 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 73 | -0.02 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 78 | -0.11 Units on a scale | Standard Deviation 1.11 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 79 | -0.13 Units on a scale | Standard Deviation 0.86 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 27 | -0.39 Units on a scale | Standard Deviation 1.1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 80 | -0.35 Units on a scale | Standard Deviation 0.99 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 28 | -0.36 Units on a scale | Standard Deviation 1.07 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 82 | -0.31 Units on a scale | Standard Deviation 1.03 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 30 | -0.31 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 31 | -0.34 Units on a scale | Standard Deviation 1.11 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 83 | -0.32 Units on a scale | Standard Deviation 1.03 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 32 | -0.41 Units on a scale | Standard Deviation 1.02 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 33 | -0.35 Units on a scale | Standard Deviation 0.97 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 84 | -0.33 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 36 | -0.39 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 37 | -0.22 Units on a scale | Standard Deviation 0.94 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 87 | -0.25 Units on a scale | Standard Deviation 1.1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 43 | -0.38 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 90 | -0.04 Units on a scale | Standard Deviation 1.25 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 44 | -0.48 Units on a scale | Standard Deviation 1.21 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 45 | -0.32 Units on a scale | Standard Deviation 1.11 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 94 | -0.23 Units on a scale | Standard Deviation 1.35 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 95 | 0.14 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 96 | 0.09 Units on a scale | Standard Deviation 1.53 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 100 | -0.15 Units on a scale | Standard Deviation 1.43 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 101 | -0.10 Units on a scale | Standard Deviation 1.54 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 102 | -0.25 Units on a scale | Standard Deviation 0.88 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 103 | -0.56 Units on a scale | Standard Deviation 1.04 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 107 | -0.57 Units on a scale | Standard Deviation 1.17 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 110 | -0.50 Units on a scale | Standard Deviation 1.32 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 111 | -0.25 Units on a scale | Standard Deviation 1.26 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 112 | -0.67 Units on a scale | Standard Deviation 1.15 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 52 | -0.33 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 53 | -0.28 Units on a scale | Standard Deviation 1.14 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 54 | -0.45 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 55 | -0.38 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 56 | -0.46 Units on a scale | Standard Deviation 1.13 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 57 | -0.36 Units on a scale | Standard Deviation 1.25 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 58 | -0.51 Units on a scale | Standard Deviation 1.14 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 59 | -0.45 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 60 | -0.41 Units on a scale | Standard Deviation 1.26 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 61 | -0.38 Units on a scale | Standard Deviation 1.27 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 65 | -0.28 Units on a scale | Standard Deviation 1.26 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 66 | -0.30 Units on a scale | Standard Deviation 1.22 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 67 | -0.44 Units on a scale | Standard Deviation 1.29 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 68 | -0.21 Units on a scale | Standard Deviation 1.36 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 69 | -0.26 Units on a scale | Standard Deviation 1.29 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 75 | -0.17 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 76 | 0.07 Units on a scale | Standard Deviation 1.16 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 77 | -0.18 Units on a scale | Standard Deviation 1.29 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 78 | -0.30 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 83 | -0.39 Units on a scale | Standard Deviation 1.06 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 87 | 0.00 Units on a scale | Standard Deviation 1.3 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 88 | -0.37 Units on a scale | Standard Deviation 1.19 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 89 | -0.29 Units on a scale | Standard Deviation 1.17 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 90 | -0.35 Units on a scale | Standard Deviation 1.14 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 95 | 0.00 Units on a scale | Standard Deviation 1.28 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 96 | -0.18 Units on a scale | Standard Deviation 1.45 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 97 | -0.14 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 98 | -0.35 Units on a scale | Standard Deviation 1.18 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 99 | 0.00 Units on a scale | Standard Deviation 1.41 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 105 | 0.08 Units on a scale | Standard Deviation 0.8 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 106 | -0.28 Units on a scale | Standard Deviation 1.23 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 107 | -0.57 Units on a scale | Standard Deviation 1.48 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 108 | -0.70 Units on a scale | Standard Deviation 1.64 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 109 | -0.30 Units on a scale | Standard Deviation 1.82 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 114 | 0.50 Units on a scale | Standard Deviation 1.8 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 116 | -0.50 Units on a scale | Standard Deviation 1.32 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 110 | -0.27 Units on a scale | Standard Deviation 0.5 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 111 | -0.15 Units on a scale | Standard Deviation 0.34 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 112 | -0.20 Units on a scale | Standard Deviation 0.4 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 113 | -0.35 Units on a scale | Standard Deviation 0.44 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 114 | -0.27 Units on a scale | Standard Deviation 0.5 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 115 | -0.40 Units on a scale | Standard Deviation 0.28 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 116 | -0.20 Units on a scale | Standard Deviation 0.53 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 117 | -0.60 Units on a scale | Standard Deviation 0.28 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 118 | -0.80 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 119 | -0.80 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 120 | -0.80 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 121 | -0.80 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 122 | -0.80 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 123 | -0.80 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 124 | -0.80 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Time of First Pd | 0.42 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 119 | 1.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 120 | 1.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 121 | 1.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 122 | 1.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 123 | 1.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 124 | 2.00 Units on a scale | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Time of First Pd | -0.16 Units on a scale | Standard Deviation 1.12 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Time of Last Tx Dose | -0.24 Units on a scale | Standard Deviation 1.09 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 1 | 0.11 Units on a scale | Standard Deviation 0.76 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 2 | 0.11 Units on a scale | Standard Deviation 0.86 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 3 | 0.16 Units on a scale | Standard Deviation 0.81 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 4 | 0.16 Units on a scale | Standard Deviation 0.83 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 5 | 0.25 Units on a scale | Standard Deviation 0.88 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 6 | 0.23 Units on a scale | Standard Deviation 0.83 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 7 | 0.25 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 8 | 0.29 Units on a scale | Standard Deviation 0.91 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 46 | 0.08 Units on a scale | Standard Deviation 0.78 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 47 | 0.06 Units on a scale | Standard Deviation 0.8 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 48 | 0.14 Units on a scale | Standard Deviation 0.85 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 49 | 0.06 Units on a scale | Standard Deviation 0.78 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 50 | 0.10 Units on a scale | Standard Deviation 0.85 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 51 | 0.08 Units on a scale | Standard Deviation 0.78 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 52 | 0.11 Units on a scale | Standard Deviation 0.86 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 53 | 0.11 Units on a scale | Standard Deviation 0.89 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 54 | 0.11 Units on a scale | Standard Deviation 0.8 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 55 | 0.15 Units on a scale | Standard Deviation 0.85 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 56 | 0.14 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 57 | 0.12 Units on a scale | Standard Deviation 0.9 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 58 | 0.02 Units on a scale | Standard Deviation 0.98 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 59 | 0.11 Units on a scale | Standard Deviation 1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 60 | 0.06 Units on a scale | Standard Deviation 0.93 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 61 | 0.05 Units on a scale | Standard Deviation 0.92 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 62 | 0.01 Units on a scale | Standard Deviation 0.96 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 63 | 0.10 Units on a scale | Standard Deviation 0.95 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 64 | 0.07 Units on a scale | Standard Deviation 1.08 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 65 | 0.05 Units on a scale | Standard Deviation 1.05 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 66 | 0.04 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 58 | 0.12 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 68 | -0.66 Units on a scale | Standard Deviation 1.17 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 7 | -0.47 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 4 | 0.26 Units on a scale | Standard Deviation 0.89 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 69 | -0.78 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 33 | -0.10 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 22 | 0.24 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 75 | -1.04 Units on a scale | Standard Deviation 1.29 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 6 | -0.35 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 5 | 0.31 Units on a scale | Standard Deviation 0.85 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 76 | -1.18 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 32 | -0.16 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 122 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 77 | -0.60 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 31 | -0.15 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 64 | -0.22 Units on a scale | Standard Deviation 0.74 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 78 | -0.86 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 6 | 0.29 Units on a scale | Standard Deviation 0.88 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 83 | -1.00 Units on a scale | Standard Deviation 1.2 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 30 | -0.08 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 59 | -0.03 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 87 | -0.94 Units on a scale | Standard Deviation 1.35 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 29 | -0.18 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 7 | 0.27 Units on a scale | Standard Deviation 0.96 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 121 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 89 | -1.14 Units on a scale | Standard Deviation 1.31 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 28 | -0.19 Units on a scale | Standard Deviation 1.24 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 21 | 0.19 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 90 | -0.79 Units on a scale | Standard Deviation 1.29 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 27 | 0.04 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 45 | 0.27 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 95 | -0.81 Units on a scale | Standard Deviation 1.31 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 26 | -0.11 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 120 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 96 | -1.00 Units on a scale | Standard Deviation 1.31 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 25 | -0.20 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 11 | -0.50 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 97 | -0.78 Units on a scale | Standard Deviation 1.23 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 24 | -0.17 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 46 | 0.26 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 98 | -1.00 Units on a scale | Standard Deviation 1.29 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 23 | -0.10 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 119 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 99 | -0.64 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 60 | 0.02 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 105 | -0.25 Units on a scale | Standard Deviation 1.33 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 22 | -0.14 Units on a scale | Standard Deviation 1.16 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 47 | 0.31 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 106 | -0.80 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 21 | -0.18 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 118 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 107 | -1.25 Units on a scale | Standard Deviation 1.19 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 20 | -0.17 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 19 | 0.44 Units on a scale | Standard Deviation 0.96 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 108 | -1.38 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 19 | -0.16 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 48 | 0.22 Units on a scale | Standard Deviation 0.93 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 109 | -0.75 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 18 | -0.17 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 117 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 114 | -1.50 Units on a scale | Standard Deviation 0.71 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 17 | -0.24 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 115 | -1.00 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 16 | -0.23 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 66 | -0.18 Units on a scale | Standard Deviation 0.85 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 116 | -1.33 Units on a scale | Standard Deviation 1.15 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 49 | 0.14 Units on a scale | Standard Deviation 0.93 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 110 | -0.40 Units on a scale | Standard Deviation 0.94 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 15 | -0.17 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 116 | -0.67 Units on a scale | Standard Deviation 0.58 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 111 | -0.45 Units on a scale | Standard Deviation 0.91 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 14 | -0.15 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 61 | -0.18 Units on a scale | Standard Deviation 0.93 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 112 | -1.30 Units on a scale | Standard Deviation 0.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 13 | -0.17 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 50 | 0.06 Units on a scale | Standard Deviation 0.86 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 113 | -0.47 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 12 | -0.30 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 115 | -0.67 Units on a scale | Standard Deviation 0.58 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 114 | -1.30 Units on a scale | Standard Deviation 0.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 11 | -0.09 Units on a scale | Standard Deviation 1.16 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 17 | 0.29 Units on a scale | Standard Deviation 0.91 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 115 | -0.67 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 5 | -0.19 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 51 | 0.15 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 116 | -0.73 Units on a scale | Standard Deviation 1.17 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 10 | -0.08 Units on a scale | Standard Deviation 1.19 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 114 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 117 | -1.20 Units on a scale | Standard Deviation 0.28 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 9 | -0.21 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 65 | -0.18 Units on a scale | Standard Deviation 0.87 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 118 | -1.20 Units on a scale | Standard Deviation 0.57 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 52 | 0.34 Units on a scale | Standard Deviation 0.97 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 119 | -1.40 Units on a scale | Standard Deviation 0.28 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 2 | 0.28 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 120 | -1.10 Units on a scale | Standard Deviation 0.42 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 62 | -0.04 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 121 | -1.30 Units on a scale | Standard Deviation 0.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 53 | 0.11 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 122 | -1.30 Units on a scale | Standard Deviation 0.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 1 | 0.44 Units on a scale | Standard Deviation 1.03 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 123 | -1.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 110 | -1.25 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 124 | -1.20 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 125 | -1.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 126 | -1.20 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 127 | -1.20 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 4 | -0.33 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 54 | 0.10 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 92 | -0.10 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 119 | -1.00 Units on a scale | Standard Deviation 0.71 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 1 | -0.02 Units on a scale | Standard Deviation 0.74 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 120 | -1.00 Units on a scale | Standard Deviation 0.71 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 55 | 0.16 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 83 | -0.05 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 31 | -0.49 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 30 | -0.54 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 121 | -1.00 Units on a scale | Standard Deviation 0.71 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 32 | -0.53 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 82 | 0.22 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 89 | -0.06 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 33 | -0.53 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 28 | -0.52 Units on a scale | Standard Deviation 1.21 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 122 | -1.25 Units on a scale | Standard Deviation 0.35 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 84 | 0.35 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 80 | 0.09 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 86 | 0.33 Units on a scale | Standard Deviation 1.37 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 35 | -0.47 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 27 | -0.31 Units on a scale | Standard Deviation 1.2 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 63 | -0.06 Units on a scale | Standard Deviation 0.72 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 36 | -0.43 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 79 | 0.17 Units on a scale | Standard Deviation 0.94 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 123 | -2.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 37 | -0.54 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 78 | 0.00 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 72 | -0.14 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 56 | 0.12 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 124 | -1.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 89 | -0.29 Units on a scale | Standard Deviation 1.25 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 71 | -0.43 Units on a scale | Standard Deviation 1.22 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 125 | -2.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 90 | 0.00 Units on a scale | Standard Deviation 1.29 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 43 | -0.45 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 70 | -0.32 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 126 | -1.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 44 | -0.56 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 26 | -0.54 Units on a scale | Standard Deviation 1.24 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 127 | -1.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 45 | -0.69 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 65 | -0.25 Units on a scale | Standard Deviation 1.21 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 8 | -0.17 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 94 | 0.00 Units on a scale | Standard Deviation 1.2 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 25 | -0.52 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 83 | -0.40 Units on a scale | Standard Deviation 0.98 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 95 | 0.25 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 61 | -0.34 Units on a scale | Standard Deviation 1.23 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Time of First Pd | -0.16 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 96 | 0.19 Units on a scale | Standard Deviation 0.92 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 7 | -0.14 Units on a scale | Standard Deviation 1.16 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 100 | 0.00 Units on a scale | Standard Deviation 1.2 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 60 | -0.26 Units on a scale | Standard Deviation 1.22 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 88 | -1.29 Units on a scale | Standard Deviation 1.41 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 101 | 0.21 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 55 | -0.15 Units on a scale | Standard Deviation 1.19 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Time of Last Tx Dose | -0.21 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 102 | 0.08 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 20 | -0.51 Units on a scale | Standard Deviation 1.15 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 3 | -0.08 Units on a scale | Standard Deviation 0.95 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 103 | 0.17 Units on a scale | Standard Deviation 1.17 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 106 | -0.40 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 18 | -0.48 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 6 | -0.20 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 107 | -0.50 Units on a scale | Standard Deviation 0.58 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 52 | 0.02 Units on a scale | Standard Deviation 1.3 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 17 | -0.48 Units on a scale | Standard Deviation 1.16 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 2 | 0.17 Units on a scale | Standard Deviation 0.87 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 110 | -0.38 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 13 | -0.46 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 5 | -0.16 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 111 | -0.38 Units on a scale | Standard Deviation 0.48 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 48 | 0.00 Units on a scale | Standard Deviation 1.32 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 3 | -0.05 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Time of Last Tx Dose | 0.05 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 52 | -0.64 Units on a scale | Standard Deviation 1.03 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 47 | 0.04 Units on a scale | Standard Deviation 1.29 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Time of First Pd | -0.11 Units on a scale | Standard Deviation 1.21 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 53 | -0.53 Units on a scale | Standard Deviation 1.19 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 10 | -0.42 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 127 | -1.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 54 | -0.63 Units on a scale | Standard Deviation 1.23 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 46 | -0.07 Units on a scale | Standard Deviation 1.33 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 126 | -0.50 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 55 | -0.68 Units on a scale | Standard Deviation 1.17 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 42 | -0.11 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 57 | 0.13 Units on a scale | Standard Deviation 1.03 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 56 | -0.51 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 41 | -0.13 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 1 | 0.17 Units on a scale | Standard Deviation 0.73 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 57 | -0.74 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 81 | -0.72 Units on a scale | Standard Deviation 1.25 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 40 | -0.06 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 125 | -0.50 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 58 | -0.67 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 39 | -0.13 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 42 | 0.29 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 59 | -0.81 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 37 | -0.08 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 2 | 0.27 Units on a scale | Standard Deviation 0.88 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 36 | -0.06 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 60 | -0.69 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 9 | -0.34 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 124 | -0.50 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 61 | -0.84 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 64 | -0.81 Units on a scale | Standard Deviation 0.93 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 35 | -0.19 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 4 | 0.09 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 65 | -0.70 Units on a scale | Standard Deviation 1.15 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 8 | -0.36 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 3 | 0.30 Units on a scale | Standard Deviation 0.89 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 66 | -0.82 Units on a scale | Standard Deviation 1.15 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 80 | -0.95 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 123 | -1.00 Units on a scale | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 67 | -0.78 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 34 | 0.02 Units on a scale | Standard Deviation 1.16 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 58 | -0.24 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 33 | 0.31 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 108 | -0.38 Units on a scale | Standard Deviation 0.75 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 50 | -0.14 Units on a scale | Standard Deviation 1.36 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 34 | 0.30 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 105 | 0.00 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 23 | -0.45 Units on a scale | Standard Deviation 1.17 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 35 | 0.38 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 104 | 0.00 Units on a scale | Standard Deviation 1.41 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 107 | -0.30 Units on a scale | Standard Deviation 0.74 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 36 | 0.37 Units on a scale | Standard Deviation 0.98 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 99 | 0.07 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 18 | 0.34 Units on a scale | Standard Deviation 0.97 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 98 | 0.00 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 90 | -0.17 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 97 | -0.11 Units on a scale | Standard Deviation 1.17 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 22 | -0.44 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 20 | 0.24 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 93 | -0.05 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 102 | 0.00 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 91 | -0.17 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 37 | 0.32 Units on a scale | Standard Deviation 0.92 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 46 | -0.67 Units on a scale | Standard Deviation 1.1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 57 | -0.27 Units on a scale | Standard Deviation 1.22 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 38 | 0.40 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 92 | 0.19 Units on a scale | Standard Deviation 1.25 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 49 | -0.09 Units on a scale | Standard Deviation 1.31 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 39 | 0.36 Units on a scale | Standard Deviation 1.01 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 91 | 0.14 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 56 | -0.08 Units on a scale | Standard Deviation 1.36 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 40 | 0.37 Units on a scale | Standard Deviation 0.91 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 42 | -0.68 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 106 | -0.04 Units on a scale | Standard Deviation 0.57 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 41 | 0.33 Units on a scale | Standard Deviation 0.89 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 41 | -0.58 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 93 | -0.14 Units on a scale | Standard Deviation 0.9 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 40 | -0.47 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 43 | 0.41 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 39 | -0.50 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 21 | -0.46 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 44 | 0.33 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 88 | 0.00 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 103 | -0.03 Units on a scale | Standard Deviation 1.24 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 38 | -0.45 Units on a scale | Standard Deviation 1.16 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 94 | -0.25 Units on a scale | Standard Deviation 0.98 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 67 | -0.24 Units on a scale | Standard Deviation 0.97 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 87 | 0.13 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 19 | -0.37 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 68 | -0.11 Units on a scale | Standard Deviation 0.86 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 34 | -0.41 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 12 | -0.46 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 95 | -0.20 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 69 | -0.20 Units on a scale | Standard Deviation 0.87 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 85 | 0.30 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 54 | -0.24 Units on a scale | Standard Deviation 1.34 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 70 | -0.18 Units on a scale | Standard Deviation 0.94 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 29 | -0.48 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 43 | 0.05 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 71 | -0.01 Units on a scale | Standard Deviation 0.82 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 81 | 0.22 Units on a scale | Standard Deviation 0.97 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 96 | -0.18 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 72 | -0.06 Units on a scale | Standard Deviation 0.79 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 77 | -0.05 Units on a scale | Standard Deviation 1.21 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 53 | -0.20 Units on a scale | Standard Deviation 1.22 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 73 | -0.11 Units on a scale | Standard Deviation 0.79 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 76 | -0.21 Units on a scale | Standard Deviation 1.25 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 104 | -0.35 Units on a scale | Standard Deviation 1.42 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 74 | -0.17 Units on a scale | Standard Deviation 0.86 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 97 | 0.04 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 75 | -0.22 Units on a scale | Standard Deviation 0.81 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 75 | -0.21 Units on a scale | Standard Deviation 1.18 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 16 | -0.52 Units on a scale | Standard Deviation 1.25 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 76 | -0.13 Units on a scale | Standard Deviation 0.9 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 45 | -0.05 Units on a scale | Standard Deviation 1.2 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 77 | 0.12 Units on a scale | Standard Deviation 0.76 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 74 | -0.38 Units on a scale | Standard Deviation 1.21 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 98 | -0.29 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 78 | -0.20 Units on a scale | Standard Deviation 0.95 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 73 | -0.08 Units on a scale | Standard Deviation 1.27 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 51 | -0.19 Units on a scale | Standard Deviation 1.24 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 79 | -0.13 Units on a scale | Standard Deviation 0.93 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 69 | -0.03 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 38 | -0.14 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 80 | 0.00 Units on a scale | Standard Deviation 0.81 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 68 | -0.53 Units on a scale | Standard Deviation 1.23 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 99 | -0.29 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 113 | -1.17 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 112 | -1.75 Units on a scale | Standard Deviation 0.35 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 81 | -0.04 Units on a scale | Standard Deviation 0.86 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 117 | -1.50 Units on a scale | Standard Deviation 0.71 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 111 | -1.25 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 67 | -0.43 Units on a scale | Standard Deviation 1.27 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 118 | -1.50 Units on a scale | Standard Deviation 0.71 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 108 | -0.40 Units on a scale | Standard Deviation 0.88 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 104 | 0.00 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 15 | -0.47 Units on a scale | Standard Deviation 1.18 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 109 | 0.10 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 103 | -0.67 Units on a scale | Standard Deviation 1.44 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Time of First Pd | 0.27 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 102 | -0.75 Units on a scale | Standard Deviation 1.44 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 82 | 0.00 Units on a scale | Standard Deviation 0.9 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Time of Last Tx Dose | 0.28 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 101 | -0.79 Units on a scale | Standard Deviation 1.32 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 100 | -0.81 Units on a scale | Standard Deviation 1.25 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 94 | -0.88 Units on a scale | Standard Deviation 1.25 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 93 | -0.90 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 92 | -0.94 Units on a scale | Standard Deviation 1.37 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 91 | -0.93 Units on a scale | Standard Deviation 1.37 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 86 | -0.42 Units on a scale | Standard Deviation 1.32 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 85 | -0.60 Units on a scale | Standard Deviation 1.6 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 8 | 0.31 Units on a scale | Standard Deviation 0.97 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 23 | 0.20 Units on a scale | Standard Deviation 0.98 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 66 | -0.47 Units on a scale | Standard Deviation 1.18 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 9 | 0.33 Units on a scale | Standard Deviation 0.98 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 79 | -0.61 Units on a scale | Standard Deviation 1.41 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 105 | 0.23 Units on a scale | Standard Deviation 0.92 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 10 | 0.34 Units on a scale | Standard Deviation 0.95 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 84 | -0.90 Units on a scale | Standard Deviation 1.26 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 64 | -0.42 Units on a scale | Standard Deviation 1.33 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 11 | 0.35 Units on a scale | Standard Deviation 0.97 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 74 | -1.04 Units on a scale | Standard Deviation 1.21 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 100 | -0.20 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 12 | 0.29 Units on a scale | Standard Deviation 0.9 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 73 | -1.00 Units on a scale | Standard Deviation 1.38 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 84 | -0.22 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 13 | 0.34 Units on a scale | Standard Deviation 0.94 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 72 | -0.72 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 63 | -0.55 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 14 | 0.34 Units on a scale | Standard Deviation 0.91 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 71 | -0.90 Units on a scale | Standard Deviation 1.21 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 85 | -0.16 Units on a scale | Standard Deviation 1.03 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 15 | 0.30 Units on a scale | Standard Deviation 0.91 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 62 | -0.36 Units on a scale | Standard Deviation 0.96 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 16 | 0.36 Units on a scale | Standard Deviation 0.92 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 70 | -0.92 Units on a scale | Standard Deviation 1.18 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 63 | -0.82 Units on a scale | Standard Deviation 0.99 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 82 | -0.44 Units on a scale | Standard Deviation 1.13 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 14 | -0.50 Units on a scale | Standard Deviation 1.16 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 24 | 0.29 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 62 | -0.78 Units on a scale | Standard Deviation 1.04 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 86 | -0.17 Units on a scale | Standard Deviation 1.26 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 25 | 0.25 Units on a scale | Standard Deviation 1 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 51 | -0.69 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 24 | -0.46 Units on a scale | Standard Deviation 1.11 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 26 | 0.39 Units on a scale | Standard Deviation 1.02 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 50 | -0.72 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 27 | 0.36 Units on a scale | Standard Deviation 1.14 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 49 | -0.63 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 44 | -0.10 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 28 | 0.30 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 48 | -0.55 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 87 | -0.25 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 29 | 0.31 Units on a scale | Standard Deviation 1.07 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Cough, Week 47 | -0.54 Units on a scale | Standard Deviation 0.97 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 59 | -0.28 Units on a scale | Standard Deviation 1.17 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 30 | 0.39 Units on a scale | Standard Deviation 1.08 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 113 | -0.67 Units on a scale | Standard Deviation 0.58 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 101 | -0.03 Units on a scale | Standard Deviation 1.09 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 31 | 0.36 Units on a scale | Standard Deviation 1.12 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 112 | -1.00 Units on a scale | Standard Deviation 0 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 88 | -0.51 Units on a scale | Standard Deviation 1.06 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Dyspnoea, Week 32 | 0.26 Units on a scale | Standard Deviation 1.05 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population | Chest Pain, Week 109 | 0.25 Units on a scale | Standard Deviation 1.77 |
Secondary
Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.
Time frame: Up to approximately 30 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | 5.2 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | 7.2 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | 7.0 Months |
p-value: <0.000195% CI: [0.408, 0.689]Log Rank
p-value: 0.000795% CI: [0.493, 0.831]Log Rank
Secondary
Event Free Rate at 1 and 2 Years in the ITT Population
Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.
Time frame: 1 and 2 years
Population: Participants still alive at 1 or 2 years after randomization from the ITT population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Event Free Rate at 1 and 2 Years in the ITT Population | 2 Year | 26.58 Percentage of participants |
| Arm C: Nab-Paclitaxel + Carboplatin | Event Free Rate at 1 and 2 Years in the ITT Population | 1 Year | 56.28 Percentage of participants |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Event Free Rate at 1 and 2 Years in the ITT Population | 2 Year | 32.51 Percentage of participants |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Event Free Rate at 1 and 2 Years in the ITT Population | 1 Year | 56.34 Percentage of participants |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Event Free Rate at 1 and 2 Years in the ITT Population | 2 Year | 27.79 Percentage of participants |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Event Free Rate at 1 and 2 Years in the ITT Population | 1 Year | 52.30 Percentage of participants |
Comparison: Event Free Rate (%) at Year 1p-value: 0.987195% CI: [-7.48, 7.61]Z-test
Comparison: Event Free Rate (%) at Year 2p-value: 0.113395% CI: [-1.41, 13.26]Z-test
Comparison: Event Free Rate (%) at Year 1p-value: 0.307295% CI: [-11.6, 3.65]Z-test
Comparison: Event Free Rate (%) at Year 2p-value: 0.74395% CI: [-6.01, 8.42]Z-test
Secondary
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.
Time frame: Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)
Population: The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Maximum Observed Serum Atezolizumab Concentration (Cmax) | Cycle 1 Day 1 Post dose | 372 µg/mL | Standard Deviation 116 |
| Arm C: Nab-Paclitaxel + Carboplatin | Maximum Observed Serum Atezolizumab Concentration (Cmax) | Cycle 3 Day 1 Post dose | 470 µg/mL | Standard Deviation 147 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Maximum Observed Serum Atezolizumab Concentration (Cmax) | Cycle 1 Day 1 Post dose | 378 µg/mL | Standard Deviation 124 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Maximum Observed Serum Atezolizumab Concentration (Cmax) | Cycle 3 Day 1 Post dose | 444 µg/mL | Standard Deviation 119 |
Secondary
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration.
Time frame: Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 30 months), at treatment discontinuation (up to 30 months), and at 120 days after the last dose of atezolizumab (up to approximately 30 months, each cycle is 21 days)
Population: The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 4 Day 1 | 128 µg/mL | Standard Deviation 62.3 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 24 Day 1 | 187 µg/mL | Standard Deviation 90.4 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 3 Day 1 | 103 µg/mL | Standard Deviation 40.1 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 32 Day 1 | 242 µg/mL | Standard Deviation 88.4 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 8 Day 1 | 188 µg/mL | Standard Deviation 80.4 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 40 Day 1 | 308 µg/mL | Standard Deviation 141 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 2 Day 1 | 63.9 µg/mL | Standard Deviation 29.9 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Treatment Discontinuation Visit | 126 µg/mL | Standard Deviation 93.7 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 16 Day 1 | 201 µg/mL | Standard Deviation 79.2 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Day 120 Post Last Dose | 7.81 µg/mL | Standard Deviation 9.76 |
| Arm C: Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 1 Day 1 | NA µg/mL | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Day 120 Post Last Dose | 9.47 µg/mL | Standard Deviation 13.1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 1 Day 1 | NA µg/mL | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 2 Day 1 | 69.5 µg/mL | Standard Deviation 34.7 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 3 Day 1 | 107 µg/mL | Standard Deviation 52 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 4 Day 1 | 126 µg/mL | Standard Deviation 68.4 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 8 Day 1 | 190 µg/mL | Standard Deviation 84.6 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 16 Day 1 | 212 µg/mL | Standard Deviation 78.1 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 24 Day 1 | 224 µg/mL | Standard Deviation 134 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 32 Day 1 | 210 µg/mL | Standard Deviation 102 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Cycle 40 Day 1 | 174 µg/mL | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Minimum Observed Serum Atezolizumab Concentration (Cmin) | Treatment Discontinuation Visit | 137 µg/mL | Standard Deviation 103 |
Secondary
OS in the in the Teff Population
OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.
Time frame: Up to approximately 39 months after first participant enrolled
Population: The Teff (\>=-1.91) population and the Teff (\<-1.91) population, defined as patients in the ITT population with Teff signature expression \>=-1.91 and \<-1.91, respectively.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | OS in the in the Teff Population | Teff<-1.91 | 12.4 Month |
| Arm C: Nab-Paclitaxel + Carboplatin | OS in the in the Teff Population | Teff >=-1.91 | 16.4 Month |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | OS in the in the Teff Population | Teff >=-1.91 | 17.4 Month |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | OS in the in the Teff Population | Teff<-1.91 | 13.0 Month |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | OS in the in the Teff Population | Teff >=-1.91 | 15.2 Month |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | OS in the in the Teff Population | Teff<-1.91 | 10.5 Month |
Comparison: Teff \>=-1.91 in ITTp-value: 0.445195% CI: [0.623, 1.231]Log Rank
Comparison: Teff \>=-1.91 in ITTp-value: 0.734395% CI: [0.664, 1.335]Log Rank
Comparison: Teff \<-1.91 Negative in ITTp-value: 0.66195% CI: [0.72, 1.232]Log Rank
Comparison: Teff \<-1.91 Negative in ITTp-value: 0.089395% CI: [0.965, 1.627]Log Rank
Secondary
OS in the ITT Population (Arm A and Arm B)
OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B.
Time frame: Up to approximately 39 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | OS in the ITT Population (Arm A and Arm B) | 14.2 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | OS in the ITT Population (Arm A and Arm B) | 12.6 Months |
Secondary
OS in the TC1/2/3 or IC1/2/3 Population
OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.
Time frame: Up to approximately 39 months after first participant enrolled
Population: The PD-L1 TC1/2/3 or IC1/2/3 population is defined as participants in the ITT population with PD-L1 TC1/2/3 or IC1/2/3 expression in baseline tumor tissue.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | OS in the TC1/2/3 or IC1/2/3 Population | 15.0 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | OS in the TC1/2/3 or IC1/2/3 Population | 14.8 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | OS in the TC1/2/3 or IC1/2/3 Population | 14.9 Months |
p-value: 0.295695% CI: [0.671, 1.129]Log Rank
p-value: 0.247395% CI: [0.668, 1.109]Log Rank
Secondary
OS in the TC2/3 or IC2/3 Population
OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.
Time frame: Up to approximately 39 months after first participant enrolled
Population: The PD-L1 TC2/3 or IC2/3 population is defined as particpants in the ITT population with PD-L1 TC2/3 or IC2/3 expression in baseline tumor tissue.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | OS in the TC2/3 or IC2/3 Population | 14.5 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | OS in the TC2/3 or IC2/3 Population | 20.4 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | OS in the TC2/3 or IC2/3 Population | 14.8 Months |
p-value: 0.051895% CI: [0.524, 1.004]Log Rank
p-value: 0.284195% CI: [0.594, 1.165]Log Rank
Secondary
Percentage of Participants With Adverse Events
Percentage of participants with at least one adverse event.
Time frame: Up to approximately 68 months after first participant enrolled
Population: The safety population included all treated patients, defined as randomized patients who received any protocol treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Percentage of Participants With Adverse Events | 97.0 Percentage of participants |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Percentage of Participants With Adverse Events | 99.4 Percentage of participants |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Percentage of Participants With Adverse Events | 97.9 Percentage of participants |
Secondary
Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab
Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab.
Time frame: Up to approximately 30 months after first participant enrolled
Population: The baseline ADA evaluable population for each study treatment included participants who had a baseline ADA result. The post-baseline ADA evaluable population for each study treatment included participants who had at least one post baseline ADA result and who had received at least one dose of that study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab | Baseline evaluable participants | 3.1 Percentage of participants |
| Arm C: Nab-Paclitaxel + Carboplatin | Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab | Post-baseline evaluable participants | 48.1 Percentage of participants |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab | Baseline evaluable participants | 1.9 Percentage of participants |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab | Post-baseline evaluable participants | 21.4 Percentage of participants |
Secondary
Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
Proportion of participants with an objective response (CR or PR) in the ITT population.
Time frame: Up to approximately 30 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | 41.0 Percentage of participants |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | 49.7 Percentage of participants |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population | 49.3 Percentage of participants |
p-value: 0.024895% CI: [1.04, 1.91]Cochran-Mantel-Haenszel
p-value: 0.030895% CI: [1.03, 1.9]Cochran-Mantel-Haenszel
Secondary
PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B)
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B.
Time frame: Up to approximately 30 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B) | 6.5 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B) | 5.6 Months |
p-value: 0.400795% CI: [0.784, 1.102]Log Rank
Secondary
PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.
Time frame: Up to approximately 30 months after first participant enrolled
Population: The PD-L1 TC1/2/3 or IC1/2/3 population is defined as participants in the ITT population with PD-L1 TC1/2/3 or IC1/2/3 expression in baseline tumor tissue.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population | 5.6 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population | 7.1 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population | 7.0 Months |
p-value: <0.000195% CI: [0.48, 0.77]Log Rank
p-value: <0.000195% CI: [0.48, 0.77]Log Rank
Secondary
PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.
Time frame: Up to approximately 30 months after first participant enrolled
Population: The Teff (\>=-1.91) population and the Teff (\<-1.91) population, defined as patients in the ITT population with Teff signature expression \>=-1.91 and \<-1.91, respectively.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population | Teff >=-1.91 | 5.6 Months |
| Arm C: Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population | Teff<-1.91 | 5.7 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population | Teff >=-1.91 | 7.0 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population | Teff<-1.91 | 6.2 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population | Teff >=-1.91 | 7.0 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population | Teff<-1.91 | 5.5 Months |
Comparison: Teff\>=-1.91p-value: 0.000695% CI: [0.46, 0.81]Log Rank
Comparison: Teff\>=-1.91p-value: 0.6395% CI: [0.84, 1.33]Log Rank
Comparison: Teff\<-1.91p-value: 0.25895% CI: [0.7, 1.1]Log Rank
Comparison: Teff\<-1.91p-value: 0.6395% CI: [0.84, 1.33]Log Rank
Secondary
PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.
Time frame: Up to approximately 30 months after first participant enrolled
Population: The PD-L1 TC2/3 or IC2/3 population is defined as particpants in the ITT population with PD-L1 TC2/3 or IC2/3 expression in baseline tumor tissue.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population | 5.6 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population | 8.4 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population | 7.0 Months |
p-value: <0.000195% CI: [0.4, 0.72]Log Rank
p-value: 0.001895% CI: [0.45, 0.84]Log Rank
Secondary
Plasma Concentrations for Carboplatin
Plasma concentrations for carboplatin.
Time frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
Population: The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 Before End of Infusion | 21100 ng/mL | Standard Deviation 12400 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 After Infusion | 11900 ng/mL | Standard Deviation 6410 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 Prior to Infusion | 238 ng/mL | Standard Deviation 276 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 Before End of Infusion | 33800 ng/mL | Standard Deviation 38600 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 After Infusion | 20000 ng/mL | Standard Deviation 30900 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 After Infusion | 11200 ng/mL | Standard Deviation 5160 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 Prior to Infusion | 147 ng/mL | Standard Deviation 60.9 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 Before End of Infusion | 23500 ng/mL | Standard Deviation 21600 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 Before End of Infusion | 15900 ng/mL | Standard Deviation 9270 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 After Infusion | 9890 ng/mL | Standard Deviation 4780 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 Before End of Infusion | 24900 ng/mL | Standard Deviation 38200 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 After Infusion | 10800 ng/mL | Standard Deviation 6230 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 After Infusion | 14700 ng/mL | Standard Deviation 14600 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 Prior to Infusion | 161 ng/mL | Standard Deviation 70 |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 1 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Plasma Concentrations for Carboplatin | Cycle 3 Day 1 Before End of Infusion | 26800 ng/mL | Standard Deviation 31900 |
Secondary
Plasma Concentrations for Nab-Paclitaxel
Plasma concentrations for nab-paclitaxel.
Time frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
Population: The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 1 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 1 Day 1 Before End of Infusion | 3330 ng/mL | Standard Deviation 3680 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 1 Day 1 After Infusion | 735 ng/mL | Standard Deviation 1300 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 3 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 3 Day 1 Before End of Infusion | 7160 ng/mL | Standard Deviation 12300 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 3 Day 1 After Infusion | 296 ng/mL | Standard Deviation 274 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 3 Day 1 Before End of Infusion | 7180 ng/mL | Standard Deviation 14400 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 1 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 3 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 1 Day 1 Before End of Infusion | 8160 ng/mL | Standard Deviation 20900 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 3 Day 1 After Infusion | 1140 ng/mL | Standard Deviation 2070 |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Nab-Paclitaxel | Cycle 1 Day 1 After Infusion | 921 ng/mL | Standard Deviation 2080 |
Secondary
Plasma Concentrations for Paclitaxel
Plasma concentrations for paclitaxel.
Time frame: Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
Population: The pharmacokinetic evaluable population is defined as all participants who received any dose of atezolizumab, carboplatin, paclitaxel, or nab paclitaxel and who had evaluable PK samples post-dose.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Paclitaxel | Cycle 1 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Paclitaxel | Cycle 1 Day 1 Before end of Infusion | 5860 ng/mL | Standard Deviation 2410 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Paclitaxel | Cycle 1 Day 1 After Infusion | 2960 ng/mL | Standard Deviation 2770 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Paclitaxel | Cycle 3 Day 1 Prior to Infusion | NA ng/mL | — |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Paclitaxel | Cycle 3 Day 1 Before end of Infusion | 21900 ng/mL | Standard Deviation 42600 |
| Arm C: Nab-Paclitaxel + Carboplatin | Plasma Concentrations for Paclitaxel | Cycle 3 Day 1 After Infusion | 11000 ng/mL | Standard Deviation 30700 |
Secondary
Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population
TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems.
Time frame: Up to approximately 30 months after first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population | 3.2 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population | 4.2 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population | 3.0 Months |
p-value: 0.046195% CI: [0.638, 0.996]Log Rank
p-value: 0.729595% CI: [0.834, 1.296]Log Rank
Secondary
TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population
TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi--item scale. In this instance, symptom deterioration will be determined as a \>= 10-point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a \>= 10-point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial\>=10-point increase above baseline followed by death within 3 weeks from the last assessment. A \>= 10-point change in the EORTC scale score is perceived by patients as clinically significant.
Time frame: Up to approximately 30 months after the first participant enrolled
Population: Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm C: Nab-Paclitaxel + Carboplatin | TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population | 2.6 Months |
| Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin | TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population | 3.4 Months |
| Arm A: Atezolizumab + Paclitaxel + Carboplatin | TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population | 2.8 Months |
p-value: 0.094295% CI: [0.663, 1.033]Log Rank
p-value: 0.770995% CI: [0.776, 1.207]Log Rank